Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 291

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 291
---
 the Exchange Act which are approved by the audit committee prior to the completion of the audit).

26

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

(a)The following documents are filed as part of this Report:

(1)Financial Statements:

    Page
  
    Report of Independent Registered Public Accounting Firm 
     
    F-2
  
    Balance Sheet 
     
    F-3
  
    Statement of Operations 
     
    F-4
  
    Statement of Changes in Shareholders’ Deficit 
     
    F-5
  
    Statement of Cash Flows 
     
    F-6
  
    Notes to Financial Statements 
     
    F-7

(2)Financial Statement Schedules:

None.

(3)Exhibits:

We hereby file as part of
this Report the exhibits listed in the attached Exhibit Index. Exhibits which are incorporated herein by reference can be inspected and
copied at the public reference facilities maintained by the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Copies of such
material can also be obtained from the Public Reference Section of the SEC, 100 F Street, N.E., Washington, D.C. 20549, at prescribed
rates or on the SEC website at www.sec.gov.

    Exhibit
     
    Description
  
    1.1
     
    Underwriting Agreement, dated January 27, 2025, by and between the Company and Clear Street LLC, as representative of the underwriters (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 30, 2025).
  
    3.1
     
    Second Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 30, 2025).
  
    4.1
     
    Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 (File No. 333-281170) initially filed with the SEC on August 1, 2024).
  
    4.2
     
    Specimen Ordinary Share Certificate (incorporated by reference to Exhibit 4.2 of the Company’s Registration Statement